Septerna to Participate in Upcoming Investor Conferences
Septerna (Nasdaq: SEPN) announced management will participate in two investor conferences in November 2025: a Guggenheim fireside chat on November 10, 2025 at 4:00 p.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 12, 2025 at 4:00 p.m. ET.
Both presentations will be live webcast and available in the investors section at www.septerna.com. Replays will be archived for at least 30 days after each event.
Septerna (Nasdaq: SEPN) ha annunciato che la direzione parteciperà a due conferenze per investitori nel novembre 2025: una chiacchierata informale con Guggenheim il 10 novembre 2025 alle 16:00 ET e una chiacchierata informale al TD Cowen Immunology & Inflammation Summit il 12 novembre 2025 alle 16:00 ET.
Entrambe le presentazioni saranno trasmissioni in diretta via webcast e disponibili nella sezione investitori su www.septerna.com. Le repliche saranno archiviate per almeno 30 giorni dopo ciascun evento.
Septerna (Nasdaq: SEPN) anunció que la dirección participará en dos conferencias para inversionistas en noviembre de 2025: una charla junto a la chimenea de Guggenheim el 10 de noviembre de 2025 a las 4:00 p.m. ET y otra charla fireside del TD Cowen Immunology & Inflammation Summit el 12 de noviembre de 2025 a las 4:00 p.m. ET.
Ambas presentaciones serán transmisiones en vivo por webcast y estarán disponibles en la sección de inversores en www.septerna.com. Las repeticiones se archivarán por al menos 30 días después de cada evento.
세프테르나(Septerna, Nasdaq: SEPN)는 경영진이 2025년 11월 두 차례의 투자자 컨퍼런스에 참석할 것이라고 발표했습니다: 구겐하임의 fireside chat이 2025년 11월 10일 동부 표준시 오후 4:00에, 그리고 TD Cowen Immunology & Inflammation Summit의 fireside chat이 2025년 11월 12일 동부 표준시 오후 4:00에 열립니다.
두 발표 모두 실시간 웹캐스트로 진행되며 www.septerna.com의 투자자 섹션에서 볼 수 있습니다. 재생은 각 이벤트 후 최소 30일 동안 보관됩니다.
Septerna (Nasdaq: SEPN) a annoncé que la direction participera à deux conférences investisseurs en novembre 2025: un fireside chat chez Guggenheim le 10 novembre 2025 à 16h00 ET et un fireside chat lors du TD Cowen Immunology & Inflammation Summit le 12 novembre 2025 à 16h00 ET.
Les deux présentations seront des présentations en direct via webcast et disponibles dans la section investisseurs sur www.septerna.com. Les replays seront archivés pendant au moins 30 jours après chaque événement.
Septerna (Nasdaq: SEPN) kündigte an, dass das Management an zwei Investorenkonferenzen im November 2025 teilnehmen wird: einen Guggenheim Fireside Chat am 10. November 2025 um 16:00 Uhr ET und einen TD Cowen Immunology & Inflammation Summit Fireside Chat am 12. November 2025 um 16:00 Uhr ET.
Beide Präsentationen werden live webcast sein und im Investorenbereich unter www.septerna.com verfügbar sein. Wiederholungen werden für mindestens 30 Tage nach jeder Veranstaltung archiviert.
سبِترنا (ناسداك: SEPN) أعلنت أن الإدارة ستشارك في مؤتمرين للمستثمرين في نوفمبر 2025: جلسة fireside مع Guggenheim في 10 نوفمبر 2025 الساعة 4:00 م بتوقيت شرق الولايات المتحدة والجلسة fireside ضمن TD Cowen Immunology & Inflammation Summit في 12 نوفمبر 2025 الساعة 4:00 م بتوقيت شرق الولايات المتحدة.
كلا العرضين سيكونان بثًا مباشرًا عبر الإنترنت ومتوافران في قسم المستثمرين على www.septerna.com. سيتم أرشفة الإعادات لمدة لا تقل عن 30 يومًا بعد كل حدث.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in November:
Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside chat on Monday, November 10, 2025, at 4:00 p.m. ET
TD Cowen Immunology & Inflammation Summit
Fireside chat on Wednesday, November 12, 2025, at 4:00 p.m. ET
Live webcasts of the presentations will be available in the investors section of the company’s website at www.septerna.com. Replays will be archived for at least 30 days following each event.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com